STOCK TITAN

Acadia Healthcare Reports Strong Third Quarter 2024 Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags

Acadia Healthcare reported strong Q3 2024 results with revenue of $815.6 million, up 8.7% year-over-year. Same facility revenue increased 8.6%, driven by a 3.6% increase in revenue per patient day and 4.7% growth in patient days. Net income reached $68.1 million ($0.74 per share), while adjusted income was $84.1 million ($0.91 per share). Adjusted EBITDA grew 10.5% to $194.3 million. The company expanded its facilities, adding 15 beds and five new CTCs during Q3, now operating 164 CTCs across 32 states. Acadia updated its 2024 guidance, projecting revenue of $3.15-3.165 billion and adjusted EBITDA of $725-735 million.

Acadia Healthcare ha riportato risultati solidi per il terzo trimestre del 2024, con un fatturato di 815,6 milioni di dollari, in aumento dell'8,7% rispetto all'anno precedente. I ricavi della stessa struttura sono aumentati dell'8,6%, grazie a un incremento del 3,6% dei ricavi per giorno paziente e un aumento del 4,7% nei giorni di degenza. L'utile netto ha raggiunto 68,1 milioni di dollari (0,74 dollari per azione), mentre l'utile rettificato è stato di 84,1 milioni di dollari (0,91 dollari per azione). L'EBITDA rettificato è aumentato del 10,5% raggiungendo 194,3 milioni di dollari. L'azienda ha ampliato le sue strutture, aggiungendo 15 letti e cinque nuovi CTC durante il terzo trimestre, ora operando con 164 CTC in 32 stati. Acadia ha aggiornato le sue previsioni per il 2024, stimando un fatturato tra 3,15 e 3,165 miliardi di dollari e un EBITDA rettificato tra 725 e 735 milioni di dollari.

Acadia Healthcare informó resultados sólidos para el tercer trimestre de 2024, con ingresos de 815.6 millones de dólares, un aumento del 8.7% en comparación con el año anterior. Los ingresos de las mismas instalaciones aumentaron un 8.6%, impulsados por un incremento del 3.6% en los ingresos por día de paciente y un crecimiento del 4.7% en días de pacientes. El ingreso neto alcanzó 68.1 millones de dólares (0.74 dólares por acción), mientras que el ingreso ajustado fue de 84.1 millones de dólares (0.91 dólares por acción). El EBITDA ajustado creció un 10.5% hasta 194.3 millones de dólares. La compañía amplió sus instalaciones, agregando 15 camas y cinco nuevos CTC durante el tercer trimestre, ahora operando 164 CTC en 32 estados. Acadia actualizó su pronóstico para 2024, proyectando ingresos de 3.15 a 3.165 mil millones de dólares y un EBITDA ajustado de 725 a 735 millones de dólares.

Acadia Healthcare는 2024년 3분기 강력한 실적을 보고하며, 수익은 8억 1560만 달러로, 전년 대비 8.7% 증가했습니다. 동일 시설 수익은 8.6% 증가했으며, 이는 환자 하루당 수익의 3.6% 증가와 환자 수일의 4.7% 증가에 힘입은 것입니다. 순이익은 6810만 달러 (주당 0.74 달러)에 도달했으며, 조정된 소득은 8410만 달러 (주당 0.91 달러)였습니다. 조정 EBITDA는 10.5% 증가하여 1억 9430만 달러에 이르렀습니다. 이 회사는 3분기 동안 15개의 침대와 5개의 새로운 CTC를 추가하여 시설을 확장했으며, 현재 32개 주에서 164개의 CTC를 운영하고 있습니다. Acadia는 2024년 예상치를 업데이트하며, 31.5억에서 31.65억 달러의 수익과 7.25억에서 7.35억 달러의 조정 EBITDA를 예상하고 있습니다.

Acadia Healthcare a annoncé de solides résultats pour le troisième trimestre 2024, avec un chiffre d'affaires de 815,6 millions de dollars, en hausse de 8,7 % par rapport à l'année précédente. Les revenus des mêmes installations ont augmenté de 8,6 %, soutenus par une augmentation de 3,6 % des revenus par jour de patient et une croissance de 4,7 % des jours de patient. Le revenu net a atteint 68,1 millions de dollars (0,74 dollar par action), tandis que le revenu ajusté s'est élevé à 84,1 millions de dollars (0,91 dollar par action). L'EBITDA ajusté a augmenté de 10,5 % pour atteindre 194,3 millions de dollars. L'entreprise a élargi ses installations en ajoutant 15 lits et cinq nouveaux CTC au cours du troisième trimestre, opérant désormais 164 CTC dans 32 États. Acadia a mis à jour ses prévisions pour 2024, projetant un chiffre d'affaires de 3,15 à 3,165 milliards de dollars et un EBITDA ajusté de 725 à 735 millions de dollars.

Acadia Healthcare berichtete über starke Ergebnisse im 3. Quartal 2024 mit einem Umsatz von 815,6 Millionen Dollar, was einem Anstieg von 8,7 % im Jahresvergleich entspricht. Der Umsatz der gleichen Einrichtung stieg um 8,6 %, was auf einen Anstieg von 3,6 % der Einnahmen pro Patienten-Tag und einem Wachstum von 4,7 % bei Patiententagen zurückzuführen ist. Der Nettogewinn erreichte 68,1 Millionen Dollar (0,74 Dollar pro Aktie), während das bereinigte Einkommen 84,1 Millionen Dollar (0,91 Dollar pro Aktie) betrug. Das bereinigte EBITDA wuchs um 10,5 % auf 194,3 Millionen Dollar. Das Unternehmen hat seine Einrichtungen erweitert, indem es im dritten Quartal 15 Betten und fünf neue CTCs hinzugefügt hat, und betreibt nun 164 CTCs in 32 Staaten. Acadia hat seine Prognose für 2024 aktualisiert und rechnet mit einem Umsatz von 3,15 bis 3,165 Milliarden Dollar und einem bereinigten EBITDA von 725 bis 735 Millionen Dollar.

Positive
  • Revenue growth of 8.7% YoY to $815.6 million
  • Same facility revenue increased 8.6%
  • Adjusted EBITDA grew 10.5% to $194.3 million
  • Same facility adjusted EBITDA margin improved 100 bps to 29.7%
  • Strong expansion with 15 new beds and 5 new CTCs in Q3
  • Healthy financial position with net leverage ratio of 2.5x
Negative
  • Closure of two facilities during Q3 2024
  • Reduced guidance due to facility closures ($17M revenue impact)

Insights

Acadia Healthcare delivered a robust Q3 2024 performance with notable growth metrics. Revenue increased by 8.7% to $815.6 million, driven by strong same-facility revenue growth of 8.6%. The company's operational efficiency is evident in the 100 basis points improvement in same-facility adjusted EBITDA margin to 29.7%.

The expansion strategy remains on track with 15 new beds added to existing facilities and 5 new CTCs launched in Q3. With a healthy balance sheet showing a net leverage ratio of 2.5x and $403.6 million in available liquidity, Acadia is well-positioned to fund its growth initiatives. The revised 2024 guidance, projecting revenue of $3.15-3.165 billion and adjusted EBITDA of $725-735 million, reflects strategic facility closures while maintaining a strong growth trajectory.

The expansion of Acadia's treatment network demonstrates strong market positioning in behavioral healthcare. Operating 164 CTCs across 32 states serving 72,000 daily patients shows significant scale advantages. The strategic joint venture partnerships with major health systems like Henry Ford Health and Intermountain Health enhance market penetration and credibility.

The planned addition of approximately 1,200 beds, with 1,000 expected to be licensed by year-end, indicates substantial capacity growth. The 4.7% increase in patient days coupled with 3.6% higher revenue per patient day suggests strong demand and pricing power. This expansion strategy, particularly in partnership with established healthcare systems, positions Acadia well for sustained growth in the behavioral health market.

Provides Updated Guidance for 2024

FRANKLIN, Tenn.--(BUSINESS WIRE)-- Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the third quarter and nine months ended September 30, 2024.

Third Quarter Highlights

  • Revenue totaled $815.6 million, an increase of 8.7% over the third quarter of 2023
  • Same facility revenue increased 8.6% compared with the third quarter of 2023, including an increase in revenue per patient day of 3.6% and an increase in patient days of 4.7%
  • Net income attributable to Acadia totaled $68.1 million, or $0.74 per diluted share
  • Adjusted income attributable to Acadia totaled $84.1 million, or $0.91 per diluted share
  • Adjusted EBITDA totaled $194.3 million, an increase of 10.5% over the third quarter of 2023, excluding provider relief funds
  • Same facility adjusted EBITDA margin increased 100 bps to 29.7% over the third quarter of 2023

Adjusted income attributable to Acadia and Adjusted EBITDA are non-GAAP financial measures. A reconciliation of all non-GAAP financial measures in this press release begins on page 8.

Third Quarter Results
Chris Hunter, Chief Executive Officer of Acadia Healthcare Company, remarked, “Our financial results for the third quarter of 2024 reflect continued execution of our growth strategy. We have the scale and expertise to support patients across the continuum of care. We are proud of the important work we are doing and are committed to providing safe, quality care for the patients, families and communities we serve while creating long-term value for our stockholders.”

Strategic Investments for Long-Term Growth
During the third quarter of 2024, the Company continued to make progress in meeting its strategic growth objectives. This includes the addition of 15 beds to existing facilities and the addition of five new CTCs during the quarter. With these additions, Acadia now operates 164 CTCs across 32 states treating over 72,000 patients daily and remains on track to open up to 14 new CTCs for the full year.

In the first nine months of the year, the Company opened 79 new beds at existing facilities. For the full year, the Company expects to open over 400 new beds at existing facilities, including over 300 beds expected in the fourth quarter.

In the first nine months of the year, the Company also opened two new facilities, totaling 120 beds. The Company remains on pace to complete construction on several additional new wholly owned and joint venture facilities, totaling nearly 700 new beds in the fourth quarter, including joint venture hospitals in partnership with Henry Ford Health in Detroit, Michigan, and Intermountain Health in Denver, Colorado, as well as a new de novo facility in Madison, Wisconsin, which was completed in October. The number of new beds available to serve patients by the end of the fourth quarter is subject to the timing of anticipated state-issued licenses.

Acadia has 21 joint venture partnerships for 22 hospitals, with 11 hospitals already in operation and 11 additional hospitals expected to open in the coming years.

Cash and Liquidity
Maintaining a strong financial position to support growth investments and disciplined capital allocation are top priorities for Acadia. As of September 30, 2024, the Company had $82.1 million in cash and cash equivalents and $321.5 million available under its $600 million revolving credit facility with a net leverage ratio of approximately 2.5x.

Net leverage ratio is a non-GAAP financial measure. A reconciliation of all non-GAAP financial measures in this press release begins on page 8.

2024 Financial Guidance
Acadia today revised its previously announced financial guidance for 2024. Revised guidance reflects the closure of two facilities during the third quarter(2).

 

 

         

2024 Guidance Range

Revenue(1)

 

 

 

 

 

$3.150 to $3.165 billion

Adjusted EBITDA(1)

 

 

 

 

 

$725 to $735 million

Adjusted earnings per diluted share(1)

 

 

 

 

 

$3.35 to $3.45

Interest expense

 

 

 

 

 

$110 to $120 million

Tax rate

 

 

 

 

 

24.5% to 25.5%

Depreciation and amortization expense

 

 

 

 

 

$145 to $155 million

Stock compensation expense

 

 

 

 

 

$40 to $45 million

Operating cash flows

 

 

 

 

 

$525 to $550 million

Expansion capital expenditures

 

 

 

 

 

$550 to $595 million

Maintenance and IT capital expenditures

 

 

 

 

 

$95 to $105 million 

Total bed additions, excluding acquisitions(3)

 

 

 

 

 

Approx. 1,200 beds

 

         

 

(1)

Includes one-time state payments of approximately $10 million (or $0.09 per diluted share) for the year, of which approximately $7 million was received in the first quarter of 2024 and the remainder in the third quarter of 2024. 

(2)

Prior full-year guidance assumed approximately $17 million of revenue and approximately $1 million of EBITDA contribution in the second half of the year from facilities that were closed during the third quarter. 

(3)

Company anticipates completing construction on approximately 1,200 beds, of which approximately 1,000 are expected to be licensed and available to serve patients by year end, with the remaining beds expected to receive licensure in the first quarter. The exact number of beds available to serve patients at year end will depend on timing of anticipated required licenses.

 

The Company’s guidance does not include the impact of any future acquisitions, divestitures, transaction, legal and other costs or non-recurring legal settlements expense.

Conference Call
Acadia will hold a conference call to discuss its third quarter financial results at 8:00 a.m. Central Time/9:00 a.m. Eastern Time on Thursday, October 31, 2024. A live webcast of the conference call will be available at www.acadiahealthcare.com in the “Investors” section of the website. The webcast of the conference call will be available for 30 days.

About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of September 30, 2024, Acadia operated a network of 260 behavioral healthcare facilities with approximately 11,300 beds in 38 states and Puerto Rico. With approximately 23,500 employees serving more than 80,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Forward-Looking Information
This press release contains forward-looking statements. Generally, words such as “may,” “will,” “should,” “could,” “anticipate,” “expect,” “intend,” “estimate,” “plan,” “continue,” and “believe” or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our facility expansions, acquisitions, joint ventures and de novo transactions; (ii) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (iii) potential reductions in payments received by Acadia from government and commercial payors; (iv) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (v) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (vi) potential disruptions to our information technology systems or a cybersecurity incident; and (vii) potential operating difficulties, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes; increased costs relating to labor, supply chain and other expenditures; changes in competition and client preferences; and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies. These factors and others are more fully described in Acadia’s periodic reports and other filings with the SEC.

 
 
 

Acadia Healthcare Company, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

(In thousands, except per share amounts)

 
Revenue

 $

            815,634

 

 $

            750,334

 

 $

        2,379,725

 

 $

        2,185,938

 

 
Salaries, wages and benefits (including equity-based compensation expense of $9,467, $8,163, $27,014 and $23,140, respectively)

 

  428,147

 

 

  394,150

 

 

  1,265,427

 

 

  1,171,960

 

Professional fees 

 

  48,498

 

 

  45,540

 

 

  142,236

 

 

  130,468

 

Supplies 

 

  29,623

 

 

  27,147

 

 

  84,153

 

 

  79,312

 

Rents and leases 

 

  12,389

 

 

  11,731

 

 

  36,141

 

 

  34,880

 

Other operating expenses 

 

  112,137

 

 

  104,048

 

 

  322,900

 

 

  290,798

 

Income from provider relief fund

 

  —

 

 

  (4,442

)

 

  —

 

 

  (4,442

)

Depreciation and amortization 

 

  37,641

 

 

  33,388

 

 

  110,054

 

 

  96,969

 

Interest expense, net

 

  29,924

 

 

  20,742

 

 

  86,297

 

 

  61,651

 

Legal settlements expense

 

  —

 

 

  394,181

 

 

  —

 

 

  394,181

 

Loss on impairment

 

  10,459

 

 

  —

 

 

  11,459

 

 

  8,694

 

Transaction, legal and other costs

 

  8,249

 

 

  11,247

 

 

  17,187

 

 

  26,792

 

Total expenses 

 

               717,067

 

 

            1,037,732

 

 

            2,075,854

 

 

            2,291,263

 

Income (loss) before income taxes

 

                  98,567

 

 

             (287,398

)

 

               303,871

 

 

             (105,325

)

Provision for (benefit from) income taxes 

 

                  27,199

 

 

               (71,873

)

 

                  72,916

 

 

               (29,907

)

Net income (loss)

 

                  71,368

 

 

             (215,525

)

 

               230,955

 

 

               (75,418

)

Net income attributable to noncontrolling interests

 

                  (3,236

)

 

                  (2,185

)

 

                  (7,958

)

 

                  (3,978

)

Net income (loss) attributable to Acadia Healthcare Company, Inc.

 $

              68,132

 

 $

          (217,710

)

 $

            222,997

 

 $

            (79,396

)

 
Earnings (loss) per share attributable to Acadia Healthcare Company, Inc. stockholders: 
Basic 

 $

                   0.74

 

 $

                 (2.39

)

 $

                   2.44

 

 $

                 (0.87

)

Diluted 

 $

                   0.74

 

 $

                 (2.39

)

 $

                   2.42

 

 $

                 (0.87

)

 
Weighted-average shares outstanding: 
Basic 

 

                  91,720

 

 

                  91,168

 

 

                  91,571

 

 

                  90,852

 

Diluted 

 

                  92,188

 

 

                  91,168

 

 

                  92,119

 

 

                  90,852

 

 
 
 
 

Acadia Healthcare Company, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

 

September 30,

 

December 31,

     

2024

 

2023

     

(In thousands) 

  
ASSETS 
Current assets:          
Cash and cash equivalents    

 $

                      82,145

 $

                    100,073

Accounts receivable, net   

 

                       383,945

 

                       361,451

Other current assets    

 

                       185,972

 

                       134,476

Total current assets    

 

                       652,062

    

 

                       596,000

Property and equipment, net

 

                    2,679,807

 

                    2,266,610

Goodwill    

 

                    2,264,851

 

                    2,225,962

Intangible assets, net    

 

                          73,139

 

                          73,278

Deferred tax assets

 

                            2,706

 

                            6,658

Operating lease right-of-use assets

 

                       122,771

 

                       117,780

Other assets    

 

                          75,121

 

                          72,553

Total assets    

 $

                5,870,457

    

 $

                5,358,841

                 
  
LIABILITIES AND EQUITY 
Current liabilities:                   
Current portion of long-term debt    

 $

                      71,694

 $

                      29,219

Accounts payable    

 

                       201,379

 

                       156,132

Accrued salaries and benefits    

 

                       141,470

 

                       141,901

Current portion of operating lease liabilities

 

                          27,175

 

                          26,268

Other accrued liabilities    

 

                       167,782

 

                       532,261

Total current liabilities    

 

                       609,500

    

 

                       885,781

Long-term debt    

 

                    1,804,825

 

                    1,342,548

Deferred tax liabilities

 

                          54,112

 

                            1,931

Operating lease liabilities

 

                       105,437

 

                       100,808

Other liabilities    

 

                       150,544

 

                       140,113

Total liabilities    

 

                    2,724,418

    

 

                    2,471,181

Redeemable noncontrolling interests

 

                       114,521

 

                       105,686

Equity:         
Common stock   

 

                                918

 

                                913

Additional paid-in capital    

 

                    2,675,882

    

 

                    2,649,340

Retained earnings   

 

                       354,718

    

 

                       131,721

Total equity    

 

                    3,031,518

    

 

                    2,781,974

Total liabilities and equity    

 $

                5,870,457

    

 $

                5,358,841

 
 
 
 

Acadia Healthcare Company, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

  

Nine Months Ended September 30,

  

 

2024

 

 

 

2023

 

  

(In thousands)

Operating activities: 
Net income (loss)

 $

                 230,955

 

 $

                 (75,418

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities: 
Depreciation and amortization 

 

  110,054

 

 

  96,969

 

Amortization of debt issuance costs 

 

  3,061

 

 

  2,485

 

Equity-based compensation expense

 

  27,014

 

 

  23,140

 

Deferred income taxes

 

  56,133

 

 

  (21,655

)

Legal settlements expense

 

  —

 

 

  394,181

 

Loss on impairment

 

  11,459

 

 

  8,694

 

Other 

 

  (3,988

)

 

  1,423

 

Change in operating assets and liabilities, net of effect of acquisitions: 
Accounts receivable, net

 

  (20,936

)

 

                    (40,227

)

Other current assets 

 

  (3,334

)

 

                    (77,165

)

Other assets 

 

  676

 

 

                            309

 

Accounts payable and other accrued liabilities

 

  (404,942

)

 

                      23,057

 

Accrued salaries and benefits 

 

  (1,841

)

 

                      (3,038

)

Other liabilities 

 

  8,681

 

 

                      17,723

 

Government relief funds

 

  —

 

 

  (4,442

)

Net cash provided by operating activities 

 

                      12,992

 

 

                    346,036

 

 
Investing activities: 
Cash paid for acquisitions, net of cash acquired 

 

  (53,550

)

 

  (349

)

Cash paid for capital expenditures 

 

  (486,891

)

 

  (285,410

)

Proceeds from sale of property and equipment

 

  10,227

 

 

  633

 

Other 

 

  (2,935

)

 

  (1,925

)

Net cash used in investing activities 

 

                  (533,149

)

 

                  (287,051

)

 
Financing activities: 
Borrowings on long-term debt 

 

  350,000

 

 

  —

 

Borrowings on revolving credit facility

 

  210,000

 

 

  40,000

 

Principal payments on revolving credit facility

 

  (15,000

)

 

  (35,000

)

Principal payments on long-term debt 

 

  (40,968

)

 

  (15,938

)

Payment of debt issuance costs

 

  (1,518

)

 

  —

 

Repurchase of shares for payroll tax withholding, net of proceeds from stock option exercises

 

  (824

)

 

  (45,193

)

Contributions from noncontrolling partners in joint ventures

 

  3,500

 

 

  2,538

 

Distributions to noncontrolling partners in joint ventures

 

  (2,972

)

 

  (3,480

)

Other

 

  11

 

 

  30

 

Net cash provided by (used in) financing activities 

 

                    502,229

 

 

                    (57,043

)

 
Net (decrease) increase in cash and cash equivalents

 

                    (17,928

)

 

                         1,942

 

Cash and cash equivalents at beginning of the period 

 

                    100,073

 

 

                      97,649

 

Cash and cash equivalents at end of the period 

 $

                   82,145

 

 $

                   99,591

 

  

 $

                            -

 

 $

                            -

 

Effect of acquisitions: 
Assets acquired, excluding cash 

 $

                   59,235

 

 $

                     6,766

 

Liabilities assumed 

 

  (4,185

)

 

  (128

)

Contingent consideration issued in connection with an acquisition

 

  (1,500

)

 

  —

 

Redeemable noncontrolling interest resulting from an acquisition

 

  —

 

 

  (6,289

)

Cash paid for acquisitions, net of cash acquired 

 $

                   53,550

 

 $

                         349

 

 
 
 
 

Acadia Healthcare Company, Inc.

Operating Statistics

(Unaudited, Revenue in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2024

 

 

 

2023

 

 

% Change

 

 

2024

 

 

 

2023

 

 

% Change

Same Facility Results (1)
Revenue

 $

   802,555

 

 $

   739,335

 

8.6

%

 $

2,334,956

 

 $

2,148,408

 

8.7

%

Patient Days

 

      800,880

 

 

      764,703

 

4.7

%

 

    2,332,369

 

 

     2,260,513

 

3.2

%

Admissions

 

         50,368

 

 

         49,397

 

2.0

%

 

        147,617

 

 

        147,130

 

0.3

%

Average Length of Stay (2)

 

             15.9

 

 

             15.5

 

2.7

%

 

               15.8

 

 

               15.4

 

2.8

%

Revenue per Patient Day

 $

        1,002

 

 $

           967

 

3.6

%

 $

         1,001

 

 $

             950

 

5.3

%

Adjusted EBITDA margin (3)

 

29.7

%

 

29.3

%

40 bps

 

29.3

%

 

28.8

%

50 bps
Adjusted EBITDA margin excluding income from provider relief fund

 

29.7

%

 

28.7

%

100 bps

 

29.3

%

 

28.6

%

70 bps
 
Facility Results
Revenue

 $

   815,634

 

 $

   750,334

 

8.7

%

 $

2,379,725

 

 $

2,185,938

 

8.9

%

Patient Days

 

      815,126

 

 

      779,296

 

4.6

%

 

    2,375,477

 

 

     2,306,109

 

3.0

%

Admissions

 

         51,513

 

 

         50,302

 

2.4

%

 

        151,082

 

 

        150,237

 

0.6

%

Average Length of Stay (2)

 

             15.8

 

 

             15.5

 

2.1

%

 

               15.7

 

 

               15.3

 

2.4

%

Revenue per Patient Day

 $

        1,001

 

 $

           963

 

3.9

%

 $

         1,002

 

 $

             948

 

5.7

%

Adjusted EBITDA margin (3)

 

28.2

%

 

28.7

%

-50 bps

 

27.9

%

 

28.0

%

-10 bps
Adjusted EBITDA margin excluding income from provider relief fund

 

28.2

%

 

28.1

%

10 bps

 

27.9

%

 

27.8

%

10 bps
 
(1) Same facility results for the periods presented include facilities we have operated for more than one year and exclude certain closed services.
(2) Average length of stay is defined as patient days divided by admissions.
(3) For each of the three and nine months ended September 30, 2023, includes income from provider relief fund of $4.4 million
 
 
 
 

Acadia Healthcare Company, Inc.

Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted EBITDA

(Unaudited)

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

(in thousands)

 
Net income (loss) attributable to Acadia Healthcare Company, Inc.

 $

              68,132

 

 $

          (217,710

)

 $

            222,997

 

 $

            (79,396

)

Net income attributable to noncontrolling interests

 

  3,236

 

 

  2,185

 

 

  7,958

 

 

  3,978

 

Provision for (benefit from) income taxes

 

  27,199

 

 

  (71,873

)

 

  72,916

 

 

  (29,907

)

Interest expense, net

 

  29,924

 

 

  20,742

 

 

  86,297

 

 

  61,651

 

Depreciation and amortization

 

  37,641

 

 

  33,388

 

 

  110,054

 

 

  96,969

 

EBITDA

 

               166,132

 

 

             (233,268

)

 

               500,222

 

 

                  53,295

 

 
Adjustments:
Equity-based compensation expense (a)

 

                    9,467

 

 

                    8,163

 

 

                  27,014

 

 

                  23,140

 

Transaction, legal and other costs  (b)

 

  8,249

 

 

                  11,247

 

 

                  17,187

 

 

                  26,792

 

Legal settlements expense (c)

 

  —

 

 

  394,181

 

 

  —

 

 

  394,181

 

Loss on impairment (d)

 

  10,459

 

 

  —

 

 

  11,459

 

 

  8,694

 

Adjusted EBITDA

 $

            194,307

 

 $

            180,323

 

 $

            555,882

 

 $

            506,102

 

 
Adjusted EBITDA margin

 

23.8

%

 

24.0

%

 

23.4

%

 

23.2

%

 
Income from provider relief fund

 

  —

 

 

  (4,442

)

 

  —

 

 

  (4,442

)

Adjusted EBITDA excluding income from provider relief fund

 $

            194,307

 

 $

            175,881

 

 $

            555,882

 

 $

            501,660

 

 
Adjusted EBITDA margin excluding income from provider relief fund

 

23.8

%

 

23.4

%

 

23.4

%

 

22.9

%

 
 
See footnotes on page 10.
 
 
 
 

Acadia Healthcare Company, Inc.

Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to 

Adjusted Income Attributable to Acadia Healthcare Company, Inc.

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2024

 

2023

 

2024

 

2023

 

 

(in thousands, except per share amounts)

 
Net income (loss) attributable to Acadia Healthcare Company, Inc.

 $

              68,132

 $

          (217,710

)

 $

            222,997

 $

            (79,396

)

 
Adjustments to income:
Transaction, legal and other costs  (b)

 

  8,249

 

  11,247

 

 

  17,187

 

  26,792

 

Legal settlements expense (c)

 

  —

 

  394,181

 

 

  —

 

  394,181

 

Loss on impairment (d)

 

  10,459

 

  —

 

 

  11,459

 

  8,694

 

Provision for (benefit from) income taxes 

 

  27,199

 

  (71,873

)

 

  72,916

 

  (29,907

)

Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc.

 

               114,039

 

               115,845

 

 

               324,559

 

               320,364

 

Income tax effect of adjustments to income (e)

 

                  29,960

 

                  28,756

 

 

                  79,614

 

                  79,947

 

Adjusted income attributable to Acadia Healthcare Company, Inc.

 

                  84,079

 

                  87,089

 

 

               244,945

 

               240,417

 

Income from provider relief fund, net of taxes

 

  —

 

  (3,237

)

 

  —

 

  (3,237

)

Adjusted income attributable to Acadia Healthcare Company, Inc. excluding income from provider relief fund

 $

              84,079

 $

              83,852

 

 $

            244,945

 $

            237,180

 

 
Weighted-average shares outstanding - diluted (f)

 

                  92,188

 

                  91,655

 

 

                  92,119

 

                  91,684

 

 
Adjusted income attributable to Acadia Healthcare Company, Inc. per diluted share

 $

                   0.91

 $

                   0.95

 

 $

                   2.66

 $

                   2.62

 

Income from provider relief fund, net of taxes, per diluted share

 

  —

 

  (0.04

)

 

  —

 

  (0.04

)

Adjusted income attributable to Acadia Healthcare Company, Inc., excluding income from provider relief fund, per diluted share

 $

                   0.91

 $

                   0.91

 

 $

                   2.66

 $

                   2.58

 

 
 
See footnotes on page 10.
 
 
 
 
Acadia Healthcare Company, Inc.
Footnotes
We have included certain financial measures in this press release, including those listed below, which are “non-GAAP financial measures” as defined under the rules and regulations promulgated by the SEC.  These non-GAAP financial measures include, and are defined, as follows:
•  EBITDA:  net income (loss) attributable to Acadia Healthcare Company, Inc. adjusted for net income attributable to noncontrolling interests, provision for (benefit from) income taxes, net interest expense and depreciation and amortization.
•  Adjusted EBITDA: EBITDA adjusted for equity-based compensation expense, transaction, legal and other costs, legal settlements expense and loss on impairment.
•  Adjusted EBITDA excluding income from provider relief fund: Adjusted EBITDA adjusted for income from provider relief fund.
•  Adjusted EBITDA margin: Adjusted EBITDA divided by revenue.
•  Adjusted EBITDA margin excluding income from provider relief fund: Adjusted EBITDA excluding income from provider relief fund divided by revenue.
•  Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc.: net income (loss) attributable to Acadia Healthcare Company, Inc. adjusted for transaction, legal and other costs, legal settlements expense, loss on impairment and provision for (benefit from) income taxes.
•  Adjusted income attributable to Acadia Healthcare Company, Inc.: Adjusted income before income taxes attributable to Acadia Healthcare Company, Inc. adjusted for the income tax effect of adjustments to income.
•  Adjusted income attributable to Acadia Healthcare Company, Inc. excluding income from provider relief fund: Adjusted income attributable to Acadia Healthcare Company, Inc. adjusted for income from provider relief fund.
•  Net leverage ratio: Long-term debt (excluding $9.7 million of unamortized debt issuance costs, discount and premium) less cash and cash equivalents divided by Adjusted EBITDA for the trailing twelve months.
 
The non-GAAP financial measures presented herein are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). The non-GAAP financial measures presented herein are not measures of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as measures of our liquidity. Our measurements of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies. We have included information concerning the non-GAAP financial measures in this press release because we believe that such information is used by certain investors as measures of a company’s historical performance. We believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present similar non-GAAP financial measures when reporting their results. Because the non-GAAP financial measures are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, the non-GAAP financial measures, as presented, may not be comparable to other similarly titled measures of other companies. Our presentation of these non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.
 
The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses. 
 
(a) Represents the equity-based compensation expense of Acadia.
(b) Represents transaction, legal and other costs incurred by Acadia primarily related to legal, government investigations, management transition, termination, restructuring, acquisition and other similar costs.
(c) Represents legal settlements expense related to the Desert Hills litigation.
(d) Represents non-cash impairment charges related to the closure of certain facilities.
(e) Represents the income tax effect of adjustments to income based on tax rates of 26.3% and 24.8% for the three months ended September 30, 2024 and 2023, respectively, and 24.5% and 25.0% for the nine months ended September 30, 2024 and 2023, respectively.
(f) For the three and nine months ended September 30, 2023, approximately 0.5 million and 0.8 million outstanding shares of restricted stock and shares of common stock issuable upon exercise of outstanding stock option awards, respectively, have been included in the calculation of weighted-average shares outstanding-diluted. These shares are excluded from the calculation of diluted earnings per share in the condensed consolidated statement of operations because the net loss for the three and nine months ended September 30, 2023 causes such securities to be anti-dilutive.
 
 

 

Investor Contact:

Patrick Feeley

Senior Vice President, Investor Relations

(615) 861-6000

Source: Acadia Healthcare Company, Inc.

FAQ

What was Acadia Healthcare's (ACHC) revenue in Q3 2024?

Acadia Healthcare reported revenue of $815.6 million in Q3 2024, representing an 8.7% increase compared to Q3 2023.

How many CTCs does Acadia Healthcare (ACHC) operate as of Q3 2024?

Acadia Healthcare operates 164 CTCs across 32 states, treating over 72,000 patients daily.

What is Acadia Healthcare's (ACHC) updated revenue guidance for 2024?

Acadia Healthcare revised its 2024 revenue guidance to $3.150-3.165 billion.

How many new beds did Acadia Healthcare (ACHC) add in Q3 2024?

Acadia Healthcare added 15 beds to existing facilities during Q3 2024.

Acadia Healthcare Company, Inc.

NASDAQ:ACHC

ACHC Rankings

ACHC Latest News

ACHC Stock Data

3.95B
92.89M
2.97%
105.67%
6%
Medical Care Facilities
Services-specialty Outpatient Facilities, Nec
Link
United States of America
FRANKLIN